Wynzora is a topical medication formulated for the treatment of certain skin conditions. It is classified as a synthetic corticosteroid with anti-inflammatory properties. The drug functions by modulating the immune response in the skin to reduce erythema, edema, and pruritus. Upon application the active ingredient penetrates the epidermis and binds to intracellular corticosteroid receptors. This binding interferes with the transcription of inflammatory cytokines and late-phase mediators. The subsequent decrease in cytokine production leads to a reduction in redness, swelling, and itching. The localized application limits systemic exposure, allowing targeted therapy of affected areas. The overall therapeutic effect results from the suppression of inflammatory pathways without significant systemic impact.

Wynzora is a prescription medication used in the treatment of chronic plaque psoriasis. It belongs to a class of drugs known as topical calcipotriene analogues. The active ingredient modulates keratinocyte proliferation and differentiation through interaction with vitamin d receptors. By binding to these receptors it reduces excessive skin cell growth and inflammation. This mechanism helps normalize the accelerated skin turnover characteristic of psoriasis. The drug also decreases the release of pro-inflammatory cytokines from immune cells in the skin. As a result patients experience a reduction in redness scaling and itching over time. Clinical studies have demonstrated its efficacy when applied consistently to affected areas.

Wynzora may cause skin irritation at the application site. Some users report mild itching or burning sensations shortly after use. Occasional dryness or flaking of the treated skin can occur. Headaches and mild fatigue have been reported in a small percentage of patients. Rarely, increased sensitivity to sunlight may develop after topical application. Long-term exposure to high doses can potentially affect skin pigmentation.

Wynzora may cause mild scalp irritation in some users. It can lead to dryness or flaking of the treated skin. Some individuals experience itching or a burning sensation after application. Occasional skin redness may appear and usually resolves with continued use. Rarely users report unwanted facial hair growth on adjacent areas. Systemic absorption is low but has been associated with headache and dizziness in isolated cases. Joint pain and mild swelling have also been documented in clinical reports.